Do myelodysplastic syndromes have cutaneous manifestations?

Yes, MDS Does Have Cutaneous Manifestations

Myelodysplastic syndromes (MDS) can present with cutaneous manifestations, which occur in a significant minority of patients and carry important prognostic implications, particularly indicating higher-risk disease and increased risk of transformation to acute myeloid leukemia.

Types of Cutaneous Manifestations

The skin findings in MDS fall into two main categories:

Specific Cutaneous Involvement

• Myelodysplasia cutis: Direct infiltration of skin by malignant myeloid cells 1, 2

  • Previously misclassified as "histiocytoid Sweet syndrome"
  • Next-generation sequencing now confirms these represent true cutaneous involvement by MDS clones
  • Identical myeloid variants detected in both blood and skin tissue 3
  • Can masquerade as granulomatous dermatitis clinically and histologically 2

• Leukemia cutis: Frank transformation with skin infiltration 4

Paraneoplastic/Inflammatory Manifestations

• Sweet syndrome (acute febrile neutrophilic dermatosis): Most commonly reported 5

  • Presents as painful erythematous plaques with fever
  • Often atypical presentations in MDS patients

• Lupus-like manifestations 3

  • Chilblain lupus is the predominant subtype (35% of cutaneous cases)
  • Distinct from idiopathic lupus: occurs in older males, lacks typical autoimmune features
  • Represents clonal inflammation rather than classic autoimmunity

• Leucocytoclastic vasculitis 4

• Photosensitivity 4

• Prurigo nodularis 4

Clinical Significance and Prognostic Implications

The presence of cutaneous manifestations is a significant predictor of high-risk MDS 4. Key findings include:

• Patients with skin manifestations have 3.59 times higher odds of belonging to the high-risk MDS subgroup 4
• Hypergammaglobulinemia is significantly more common in MDS patients with cutaneous findings 4
• Cutaneous involvement is associated with increased risk of progression to high-grade myeloid tumors 2
• Most patients with cutaneous manifestations belong to the high-risk MDS subgroup 4

Diagnostic Approach

When evaluating suspected cutaneous manifestations in MDS patients:

1. Perform early skin biopsy of any new lesions 4

   • Histopathological examination is essential
   • Consider centralized pathology review, as 50% of cases may be reclassified upon expert review 3

2. Apply next-generation sequencing to skin tissue 3, 1

   • Helps distinguish true myelodysplasia cutis from reactive inflammatory conditions
   • Detection of identical myeloid variants in blood and skin confirms clonal involvement
   • This distinction has critical therapeutic implications

3. Evaluate for systemic inflammatory conditions

   • Check for lupus-like features, vasculitis, or other autoimmune phenomena
   • Note that these may represent clonal inflammation rather than true autoimmunity 3

Treatment Considerations

Standard dermatologic therapies are often poorly effective for MDS-associated cutaneous manifestations 3. The therapeutic approach should be:

• For atypical Sweet syndrome: Dual approach combining systemic glucocorticoids AND therapy targeting the underlying MDS 5

• For lupus-like manifestations: Clone-directed therapies (azacitidine or allogeneic hematopoietic stem cell transplant) lead to parallel hematologic and cutaneous responses in the majority of patients, whereas conventional lupus therapies are often ineffective 3

• For myelodysplasia cutis: Treatment must address the underlying hematologic malignancy 1, 2

Critical Pitfalls to Avoid

• Do not dismiss skin lesions as purely dermatologic conditions without considering MDS involvement, especially in patients with known MDS
• Do not rely solely on initial histopathology - consider expert review and molecular testing 3
• Do not treat with standard dermatologic therapies alone - these manifestations require treatment of the underlying MDS 5, 3
• Do not overlook the prognostic significance - cutaneous findings should prompt reassessment of MDS risk stratification 4